Skip to main content

Table 3 Univariate and multivariate analyses of risk factors of 2-year survival

From: High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer

Factor

Cut-off

Univariate analysis

Multivariate analysis

HR

95% CI

P -value

HR

95% CI

P -value

Lower

Upper

Lower

Upper

Serum PRTN3 (ng/ml)

>21.6

3.095

1.331

7.197

0.009

4.531

1.569

13.085

0.005

Age (years)

>65

0.786

0.387

1.595

0.505

    

Sex

Male/female

1.918

0.919

4.005

0.083

1.890

0.745

4.792

0.180

WBC count (/µl)

>8600

1.018

0.418

2.483

0.968

    

Neutrophil count (/µl)

>4920

1.520

0.751

3.075

0.245

    

CEA level (ng/ml)

>6.0

4.093

0.557

30.07

0.166

    

CA19-9 level (U/ml)

>37

1.146

0.693

3.062

0.321

    

Tumor location

Right/left

1.228

0.401

1.653

0.570

    

T category

 

1.001

0.546

1.925

0.997

    

N category

 

1.663

1.160

2.406

0.006

1.572

1.056

2.339

0.026

Metastasis

a/b/c

1.724

1.016

2.814

0.044

1.633

0.903

2.955

0.105

Operation (radical resection)

R0, 1/R2, unresected

0.241

0.103

0.561

0.001

0.133

0.046

0.383

<0.001

  1. Variables selected for the multivariate analysis were those with a univariate analysis p-value of < 0.10. 95% CI 95% confidence interval, CA19-9 carbohydrate antigen19-9, CEA Carcinoembryonic antigen, WBC White blood cell